Human interferon alpha-1b inhalation - Kexing Biopharm
Alternative Names: Human interferon α1b inhalation - Kexing Biopharm; SinogenLatest Information Update: 15 Apr 2024
At a glance
- Originator Kexing Biopharm
- Class Anti-infectives; Antibronchitics; Antineoplastics; Antivirals; Interferons; Recombinant proteins
- Mechanism of Action Interferon alpha replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Respiratory syncytial virus infections
Most Recent Events
- 09 Apr 2024 Phase-III clinical trials in Respiratory syncytial virus infections (In children) in China (Inhalation), prior to April 2024
- 09 Apr 2024 Pharmacokinetics and adverse event data from a phase I trial in Respiratory syncytial virus infections released by Kexing Biopharm
- 27 Mar 2024 Phase-III clinical trials in Respiratory syncytial virus infections (In infants) in China (Inhalation) (NCT06363370)